Similarly, in the GLADIS (Glucose Awareness in Diabetes Study) clinical trial, New et al. randomized 100 patients with insulin-treated diabetes (including 19 with T2D) to either rtCGM (Freestyle Navigator) or SMBG.35 With the small sample size, there was no improvement detected in HbA1c in the rtCGM group compared to SMBG. This evidence concerns the gene INS and type 2 diabetes mellitus.